Figure 1From: No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatinNested PCR products (in duplicate) obtained with the three primer sets specific for TUBB exon 4 in an ovarian carcinoma (from right to left, lane 1: 100 bp step ladder; lanes 2 and 3: 129 bp amplicon – set 1 primers; lanes 4 and 5: 254 bp amplicon – set 2 primers; lanes 6 and 7: 201 bp amplicon – set 3 primers).Back to article page